Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GV-Zika
- Development stage
- Preclinical
- Lead developer
- GreenVax
- Modality
- Vaccines & Immunotherapeutics
01
Overview
GV-Zika (GEV-004) is an investigational inactivated vaccine being developed by GreenVax for the prevention of Zika virus infection, with a particular focus on protecting pregnant women to prevent congenital Zika syndrome. The vaccine is produced using GreenVax's proprietary BTC (B cell T cell Collaboration) platform, which utilizes green tea-derived epigallocatechin gallate (EGCG) as an eco-friendly inactivating agent instead of traditional formalin. This platform is designed to achieve complete, irreversible viral inactivation while preserving the native viral structure, thereby inducing a balanced humoral (B cell) and cellular (T cell) immune response. GV-Zika is currently in the basic research stage.
Beyond the preview
Go deeper on GV-Zika.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GV-Zika.